Just looking at this, it appears the priorities ar
Post# of 148282
(Total Views: 500)
Posted On: 08/15/2022 7:22:38 PM
Just looking at this, it appears the priorities are:
1) Removing clinical holds
2) Advancing NASH to Phase 2b or 2b/3
3) Explore Study for patients with HIV & NASH
4) Continue mTNBC Phase 2; Explore Colon Cancer Phase 2; Explore Solid Tumor Trials, cancer trials.
5) Evaluate HIV BLA resubmission is number 5? Why is this "lumped in" with developing long acting versions of leronlimab and with pursuing proof of concept for HIV cure using AAV?
6) Covid 19 strategy review.
I guess my main concern is #5. Why is the HIV BLA re-submission placed so low on the list of priorities?
I get it, I like NASH and the HIV / NASH combo, but the BLA?
I like Cancer, mTNBC, CC and Tumors, but what about the BLA?
1) Removing clinical holds
2) Advancing NASH to Phase 2b or 2b/3
3) Explore Study for patients with HIV & NASH
4) Continue mTNBC Phase 2; Explore Colon Cancer Phase 2; Explore Solid Tumor Trials, cancer trials.
5) Evaluate HIV BLA resubmission is number 5? Why is this "lumped in" with developing long acting versions of leronlimab and with pursuing proof of concept for HIV cure using AAV?
6) Covid 19 strategy review.
I guess my main concern is #5. Why is the HIV BLA re-submission placed so low on the list of priorities?
I get it, I like NASH and the HIV / NASH combo, but the BLA?
I like Cancer, mTNBC, CC and Tumors, but what about the BLA?
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼